Dr. Reddy's Laboratories RDY · NYSE
$13.06 +1.24% (+$0.16)
Summary
58 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 34% a year over the last 3 years.
- It could repay all its net debt from 1.1 years of operating profit.
What to watch
- It cut its dividend by 81% last year.
- You pay 30.8 INR for 1 INR of yearly profit, a lot for its sector.
- It missed profit estimates 4 times in the last 8 quarters.
- It earns only 5.8 INR a year on every 100 INR of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 30.8 INR for 1 INR of yearly profit. Over the last five years it was 660.4 INR on average.
Valuation in detailIs it growing?
Yes, fastRevenue (INR)
Diluted EPS (INR)
- Analyst estimate
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 15% a year. For the next fiscal year analysts expect revenue to grow by 6.5%. Earnings per share grew by 34% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 INR of revenue goes
- Cost of sales 50 INR
- Research and development 7.1 INR
- Sales and administration 32 INR
- Taxes and other 0.6 INR
- Net profit 10.0 INR
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 INR
Out of every 100 INR of revenue, 10.0 INR is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 4.8 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.64%
- Paid out of profit
- 20%
You receive $0.08 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 6
- Hold 4
- Sell 2
Today's price within the analysts' price targets
The average target of $14.8 is 13% above today's price. 50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2026By product
The company reports no revenue by product.
By region
- Others Countries Country 35%
- UNITED STATES 35%
- India Country 19%
- Russia Country 10%
Others Countries Country brings in 35% of revenue.
Segments in detail